Description
5-HT3 Antagonists (Antiemetics) & Cardiac Safety, Using an Active Surveillance Approach
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02013-08-01$424,700
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2013-08-01(start date) | $424,700 | — | 5-HT3 Antagonists (Antiemetics) & Cardiac Safety, Using an Active Surveillance Approach |
Related records · 4
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2014-2015-Q2-00320 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $750,000 | FY2015 |
| 236-2013-2014-Q4-00343 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $449,900 | FY2014 |
| 236-2011-2012-Q3-00043 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $921,950 | FY2012 |
| 236-2011-2012-Q1-00699 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $83,940 | FY2012 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2013-2014-Q2-00760 · retrieved 2026-11-14.